Nikon CeLL innovation Co., Ltd. (Nikon CeLL innovation), a wholly-owned subsidiary of Nikon Corporation (Nikon) obtained a license to manufacture regenerative medicine products on the basis of the Law on Guaranteeing the Quality, Efficiency and Safety of products, including pharmaceuticals and medical devices.
Nikon CeLL innovation, established in 2015 to focus on contract manufacturing of regenerative medicine, has provided a wide range of process development and manufacturing services, from preclinical manufacturing to commercial manufacture of cell and gene therapy.
At our factory in Koto-ku, Tokyo, we have been operating a contract development plant since 2016 and a contract manufacturing plant since 2017. In October 2019, Nikon CeLL innovation was licensed as a cell processor on the Regenerative Medicine Safety Act basis, which is used by medical institutions such as university hospitals in preclinical and medical care outside of regenerative medicine health insurance.
Obtaining a license to manufacture regenerative medicine products is an important step towards the practical use of regenerative medicine. Nikon and Nikon CeLL Innovation will promote the implementation of new treatments for diseases currently without effective treatments. In addition, we will develop practical applications for regenerative medicine and participate in the expansion of related industries.
The information is current at the date of publication. Change without notice is possible.
(Image from press release: https://photos.webwire.com/prmedia/7/257979/257979-1.png )
This news content was configured by the editorial staff of WebWire. Linking is allowed.
Press release distribution and press release distribution services provided by WebWire.